Study to determine the Effect of Amritadi Kwatha and Guda-Haritaki in the management of Vatarakta w.s.r. to Hyperuricemia

A Clinical Study to Evaluate the Effect of Amritadi Kwatha and Guda-Haritaki in the management of Vatarakta w.s.r. to Hyperuricemia

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/05/033377

Enrollment

Registered

2021-05-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M104- Other secondary gout

Interventions

Intervention1: Amritadi Kwatha Guda-Haritaki: Amritadi Kwatha - 30 ml twice a day for 6 weeks Guda-Haritaki - 10 mg granules twice a day for 6 weeks Control Intervention1: Tab. Febuxostat: Tab. Febu

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient having S.uric acid level > 7mg/dl in males and > 6mg/dl in females with or without any associated features of joint inflammation 2. Willing to participate and able to provide signed informed consent.

Exclusion criteria

Exclusion criteria: Patient not willing for trial. Below the age of 20 and above 60 yrs. Having other problems like osteoarthritis, tubercular arthritis, rheumatoid arthritis. Suffering from chronic renal, respiratory, cardiac, hepatic and malignant disorder. Female patients who are pregnant and lactating.

Design outcomes

Primary

Measure	Time frame
Fulfillment of objective and subjective criteriaTimepoint: 6 weeks	—

Secondary

Measure	Time frame
Change in serum uric acid level from base line Change in clinical featuresTimepoint: 6 weeks	—

Countries

India

Contacts

Public ContactDr Shikha

R.G.G.P.G Ayurvedic College, Paprola

dr.skumarthakur@gmail.com9816195001

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026